Payment overview · 2025
General Payments
$569.29
34 reported records · 9 companies
Healthcare provider profile · identity verified
Gerald Norris, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BIRMINGHAM, AL · NPI 1619941838
Verified facts
What the public records show
CMS Open Payments records show Gerald Norris, M.D. received $569.29 in general payments during 2025 across 34 reported records.
PFIZER INC. accounted for 25.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Kerendia, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Myrbetriq by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 226 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 321 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $143.78 | 25.3% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $88.82 | 15.6% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $84.30 | 14.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.50 | 10.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.09 | 7.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.61 | 7.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.58 | 6.6% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $35.01 | 6.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.60 | 5.9% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $569.29 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $126.13 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $114.40 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $88.82 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $84.30 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $74.80 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $60.50 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $60.50 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $44.09 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $41.61 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $37.58 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $37.58 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $35.01 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.60 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.40 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $11.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 202 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 108 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 321 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
86 | 15 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
226 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
108 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
77 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
321 | 53 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
202 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1082 | 272 |
| Amlodipine Besylate | Amlodipine Besylate | 787 | 197 |
| Levothyroxine Sodium | Levothyroxine Sodium | 666 | 144 |
| Hydrochlorothiazide | Hydrochlorothiazide | 649 | 164 |
| Losartan Potassium | Losartan Potassium | 602 | 162 |
| Pravastatin Sodium | Pravastatin Sodium | 472 | 122 |
| Metoprolol Succinate | Metoprolol Succinate | 449 | 113 |
| Omeprazole | Omeprazole | 435 | 113 |
| Meloxicam | Meloxicam | 431 | 111 |
| Ezetimibe | Ezetimibe | 402 | 100 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 394 | 98 |
| Gabapentin | Gabapentin | 384 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 362 | 101 |
| Metformin Hcl Er | Metformin Hcl | 356 | 92 |
| Alprazolam | Alprazolam | 325 | 51 |
| Ozempic | Semaglutide | 321 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 318 | 59 |
| Duloxetine Hcl | Duloxetine Hcl | 316 | 83 |
| Simvastatin | Simvastatin | 296 | 71 |
| Clonazepam | Clonazepam | 292 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 275 | 53 |
| Lisinopril | Lisinopril | 269 | 73 |
| Potassium Chloride | Potassium Chloride | 261 | 67 |
| Montelukast Sodium | Montelukast Sodium | 260 | 72 |
| Jardiance | Empagliflozin | 226 | 33 |
| Tramadol Hcl | Tramadol Hcl | 214 | 62 |
| Eliquis | Apixaban | 202 | 39 |
| Allopurinol | Allopurinol | 198 | 50 |
| Sertraline Hcl | Sertraline Hcl | 195 | 48 |
| Furosemide | Furosemide | 190 | 51 |
| Prednisone | Prednisone | 186 | 119 |
| Metformin Hcl | Metformin Hcl | 182 | 45 |
| Trazodone Hcl | Trazodone Hcl | 182 | 45 |
| Famotidine | Famotidine | 180 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 178 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 170 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 169 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 41 |
| Pregabalin | Pregabalin | 147 | 26 |
| Lorazepam | Lorazepam | 134 | 32 |
| Spironolactone | Spironolactone | 130 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 127 | 18 |
| Methocarbamol | Methocarbamol | 118 | 32 |
| Alendronate Sodium | Alendronate Sodium | 113 | 23 |
| Azithromycin | Azithromycin | 111 | 93 |
| Farxiga | Dapagliflozin Propanediol | 111 | 21 |
| Glimepiride | Glimepiride | 111 | 29 |
| Temazepam | Temazepam | 110 | 15 |
| Doxepin Hcl | Doxepin Hcl | 109 | 27 |
| Torsemide | Torsemide | 109 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 29 |
| Mounjaro | Tirzepatide | 108 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 107 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 106 | 81 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 106 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 56 |
| Celecoxib | Celecoxib | 102 | 18 |
| Amoxicillin | Amoxicillin | 97 | 81 |
| Bupropion Xl | Bupropion Hcl | 95 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 93 | 22 |
| Carvedilol | Carvedilol | 88 | 25 |
| Buspirone Hcl | Buspirone Hcl | 87 | 25 |
| Valsartan | Valsartan | 87 | 24 |
| Myrbetriq | Mirabegron | 86 | 15 |
| Memantine Hcl | Memantine Hcl | 79 | 21 |
| Trulicity | Dulaglutide | 77 | 12 |
| Telmisartan | Telmisartan | 76 | 18 |
| Donepezil Hcl | Donepezil Hcl | 74 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 30 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 71 | 57 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 69 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 69 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 66 | 52 |
| Benazepril Hcl | Benazepril Hcl | 63 | 17 |
| Clonidine Hcl | Clonidine Hcl | 60 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 59 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 59 | suppressed |
| Estradiol | Estradiol | 57 | 18 |
| Atenolol | Atenolol | 56 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 13 |
| Finasteride | Finasteride | 56 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 56 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 55 | suppressed |
| Chlorthalidone | Chlorthalidone | 54 | 15 |
| Mirtazapine | Mirtazapine | 54 | 14 |
| Valacyclovir | Valacyclovir Hcl | 52 | 22 |
| Fluconazole | Fluconazole | 51 | 35 |
| Synthroid | Levothyroxine Sodium | 49 | 12 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 46 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | suppressed |
| Repatha Sureclick | Evolocumab | 43 | suppressed |
| Levofloxacin | Levofloxacin | 42 | 36 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 41 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Ramipril | Ramipril | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 31 |
| Clobetasol Propionate | Clobetasol Propionate | 36 | 17 |
| Eszopiclone | Eszopiclone | 36 | suppressed |
| Topiramate | Topiramate | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 16 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Hydrocortisone | Hydrocortisone | 33 | 15 |
| Levemir Flexpen | Insulin Detemir | 32 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 32 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Olanzapine | Olanzapine | 29 | suppressed |
| Gemtesa | Vibegron | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Invokana | Canagliflozin | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 24 | suppressed |
| Indapamide | Indapamide | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Oxazepam | Oxazepam | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 20 |
| Diazepam | Diazepam | 20 | suppressed |
| Lactulose | Lactulose | 20 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Colchicine | Colchicine | 19 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 13 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 16 | suppressed |
| Fluvastatin Er | Fluvastatin Sodium | 16 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 15 |
| Mupirocin | Mupirocin | 15 | 12 |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Constulose | Lactulose | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 13 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Dayvigo | Lemborexant | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 13 |
| Rybelsus | Semaglutide | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Cabergoline | Cabergoline | 12 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $569.29 · 34 records | PFIZER INC. | ABRYSVO, AREXVY, COMIRNATY, Cologuard Collection Kit, ELIQUIS, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, UBRELVY, Veozah, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error